Brett Abrahams, PhD


Dr. Abrahams serves as a clinical and scientific advisor for Accelerator. Dr. Abrahams is a geneticist turned drug hunter building early-stage neuro-focused startups. He has lead R&D activities at Magnolia Neurosciences, a Series A funded company developing small molecule therapeutics for neurodegenerative disorders, since its formation in 2018. He joined Magnolia from Ovid Therapeutics (NASDAQ: OVID) where he was Senior Director and Head, Pre-Clinical Biology. Before this, Dr. Abrahams was full-time faculty at the Albert Einstein College of Medicine, where he retains an adjunct appointment. His research, published in numerous high impact journals including Cell, New England Journal of Medicine, Nature, and Science Translational Medicine, has been cited more than 10,000 times.

Following a PhD in Neuroscience at the University of British Columbia / CMMT with Dr. Elizabeth Simpson, Dr. Abrahams did a Post-doctoral fellowship in the Dept. of Neurology at UCLA with Dr. Daniel Geschwind.